Antibodies and Infectious Disease

The perception of man as the easy victor over microbes has changed dramatically in the last two decades. Vaccination has offered protection against a number of viral pathogens, but it is increasingly recognized that the strategies used in the past will not be successful against all viruses. We are focused on developing rational vaccine strategies, particularly against HIV and particularly using an approach termed “Reverse Vaccinology 2.0”. In this approach, broadly neutralizing antibodies isolated from natural HIV infection are investigated in interaction with their sole viral target, the HIV Envelope, and the data used to guide immunogen design and immunization strategies. Immunogens are then evaluated in detail in animal models and the results used to iteratively improve immunogens as we move toward an HIV vaccine suitable to protect humans.

Featured Articles

Andrabi R, Pallesen J, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR. (2019) The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. Cell Rep. 27(8):2426-2441.

Briney B, Inderbitzin A, Joyce C, Burton DR. (2019) Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature. 566(7744):393-397.

Burton Dr. (2019) Advancing an HIV vaccine; advancing vaccinology. Nat Rev Immunol. 19(2):77-78.

Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR. (2019) Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity. 50(1):241-252.

Sok D, Burton, DR. (2018) Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 19(11):1179-1188.

Bianchi M, Turner HL, Nogal B, Cottrell CA, Oyen D, Pauthner M, Bastidas R, Nedellec R, McCoy LE, Wilson IA, Burton DR, Ward AB, Hangartner L. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity. 49(2):288-300.

Andrabi R, Bhiman JN, Burton DR. (2018) Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 53:143-151.

Walker LM, Burton DR. (2018) Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat Rev Immunol. 18(5):297-308.

Teijaro JR, Burton DR. (2018) Taking down defenses to improve vaccines. Science. 359(6373):277-278.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P. (2017) HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. Immunity. 47(5):990-1003.

Designing an HIV Vaccine - Dennis Burton | The Scripps Research Institute

Cow antibodies prove promising in developing HIV vaccine